FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.

201412 citationsJournal Article

Authors

Smal Mp · Institute of Genetics and Cytology of the National Academy of Sciences of Belarus

A.I. Rolevich · N.N. Alexandrov National Cancer Centre

Polyakov Sl · N.N. Alexandrov National Cancer Centre

Krasny Sa · N.N. Alexandrov National Cancer Centre

Goncharova Ri · Institute of Genetics and Cytology of the National Academy of Sciences of Belarus

Abstract

Our findings confirm the alternative role of FGFR3 and TP53 mutations in the development of bladder cancer. Together these two genetic markers are attributed to 62% of the tumors studied. Tumors with both wild type genes included urothelial carcinomas of all stages and grades and may develop through another genetic pathway. To elucidate complete molecular profile of bladder tumors further additional studies are needed.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Fibroblast Growth Factor Research Renal cell carcinoma treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 36, Issue 4, pp. 246-51

Field-Weighted Citation Impact: 2.00